Gain insights that can support your next steps, whether advancing to a new clinical phase, constructing a new facility, or fine-tuning an existing process to keep pace with market shifts.
The technology to measure alternative metrics is vastly improved. Now, FDA joins other regulators in deprioritizing comparative efficacy studies for biosimilars.
By J. Morris, IQS Consulting; and P. Savin, Beyond GMP Compliance
A shrinking FDA and rising supply pressures demand stronger risk management and smarter internal audits. Here’s how pharma can truly “see things as they really are.”
